QDEL logo

QUIDELORTHO CORP

QDELNASDAQ
πŸ† #2669 by market capEarnings Feb 9 Β· PostUS Equity
$8.32β–Ό $0.60 (βˆ’6.73%)
Market closed Β· at close
πŸ””
Track QDEL
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 6.7%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$571M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-1.9%
Declining
πŸ“ŠGross Margin
44.2%
Healthy
πŸ’΅FCF Margin
-4.5%
Thin
βš–οΈP/S Ratio
0.2x
Cheap
Otter Score
56
Fair
No chart data available for QDEL.

Trading Snapshot

Day Range
$8.06 – $8.95
52-Week Range
$8.06 – $35.58
Volume (shares)
2,609,859
Avg Volume (shares)
β€”
Shares Outstanding
68.6M
Next Earnings
2027-02-09

Fundamentals Snapshot

Annual Revenue
$2.73B
Last Q Revenue
$619M
P/E Ratio
-1.5
P/S Ratio
0.2x
EPS (TTM)
$-5.37
Dividend Yield
0.00%
Dilution (1yr)
+0.9%
QDEL logo

QUIDELORTHO CORP

QDEL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2.7Bβ–Ό βˆ’1.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
46.7%β–² +1.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$919Mβ–Ό βˆ’53.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$83Mβ–Ό βˆ’26.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
67.8Mβ–² +0.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$2.7Bβ–Ό βˆ’$81M YoY
StockOtter Β· stockotter.space

About QUIDELORTHO CORP

QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
56/100
Analyst data unavailable.

Latest News & Updates

PRNewsWireΒ·1d ago

QuidelOrtho Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of QuidelOrtho Corporation - QDEL

NEW ORLEANS, Nov. 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

GuruFocusΒ·6d ago

QuidelOrtho (QDEL) Securities Investigation Notice - Levi & Korsinsky

QuidelOrtho (QDEL) Securities Investigation Notice - Levi and KorsinskyPR NewswireNEW YORK, Nov. 16, 2026 QuidelOrtho shares fell roughly 14% after third-quarter

PRNewsWireΒ·10d ago

Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p

GlobeNewsWireΒ·10d ago

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving QuidelOrtho (QDEL)

Point-of-Care revenue down 27% and total sales down roughly 12% year over year: QuidelOrtho's third-quarter 2026 revenue miss against Wall Street consensus sent shares down approximately 14% Point-of-Care revenue down 27

PRNewsWireΒ·12d ago

QDEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving QuidelOrtho

QuidelOrtho's May 2026 quarterly report said China's volume-based procurement program would not likely have a material impact on total annualized revenue. Third-quarter 2026 results showed China revenue down 45%, and QDE

PRNewsWireΒ·13d ago

QuidelOrtho Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into QuidelOrtho (QDEL)

QuidelOrtho narrowed its full-year revenue outlook and announced a restructuring program with its third-quarter 2026 results, and shares fell roughly 14%. QDEL shareholders who lost money have rights, and Levi & Korsinsk